FDA Requests Survival Evidence Before Tovecimig Biologics Filing
Compass disclosed that FDA recommended a trial demonstrating overall survival benefit before a biologics license application for tovecimig in previously treated advanced biliary tract cancer. Compass disagrees that a new trial is warranted and…
